Screener
Aurinia Pharmaceuticals AUPH Accrued research and development expenses
Accrued research and development expenses at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept auph:AccruedResearchAndDevelopmentCurrent.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued sales rebates and fees | $40,330 | $30,832 |
| Accrued payroll and related expenses | 11,842 | 18,869 |
| Accrued research and development expenses | 5,634 | 6,127 |
| Accrued sales and marketing expenses | 1,304 | 1,648 |
| Accrued corporate and excise taxes | 860 | 2,010 |
| Accrued other expenses | 4,142 | 7,135 |
| Total accrued expenses | $64,112 | $66,621 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's accrued research and development expenses?
- Aurinia Pharmaceuticals (AUPH) reported accrued research and development expenses of $5.63M in Q2 2026.
- How has Aurinia Pharmaceuticals's accrued research and development expenses changed year-over-year?
- Aurinia Pharmaceuticals's accrued research and development expenses decreased by 13.3% year-over-year, from $6.5M to $5.63M.
- What does accrued research and development expenses mean?
- Accrued research and development expenses as reported by Aurinia Pharmaceuticals Inc.
Ask your AI about Aurinia Pharmaceuticals's accrued research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude